MENS

Jyong Biotech Ltd.

• Benzinga·06/29 21:05

  12 Health Care Stocks Moving In Monday's After-Market Session

• PR Newswire·06/01 00:00

  Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview

• PUBT·05/29 12:05

  Jyong Biotech CEO targets 2029-2030 FDA NDA filing for Botreso, PharmaBoardroom interview says

• PUBT·05/15 10:19

  Jyong Biotech FY25 net loss widens 55% to US$4.67 million

• TipRanks·04/29 18:19

  Jyong Biotech Delays Annual 20-F (Yearly Report)

• PUBT·04/29 17:12

  Jyong Biotech delays annual Form 20-F filing, cites audit completion needs

• PR Newswire·04/29 00:00

  Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio

• Benzinga·04/28 12:37

  Jyong Biotech Advances Market Access Strategies For Its Plant-Based Drugs Botreso And PCP After Analysis Of Their Clinical Efficacy And Competitive Advantages

• PUBT·04/14 15:46

  Jyong Biotech files Form 3; CFO Zhang Wei reports no beneficial ownership

• Reuters·04/08 14:12

  Jyong Biotech files Form 3 showing CEO Fu-Feng Kuo as 10% owner

• Reuters·04/01 19:45

  Jyong Biotech files Form 3 as director Hsu Ming Tsan reports beneficial ownership

• Reuters·04/01 19:34

  Jyong Biotech files Form 3 as director Hsu Feng-Lin reports beneficial ownership

• Reuters·04/01 19:21

  Jyong Biotech director Hsu Feng-Lin files initial beneficial ownership statement

• Reuters·04/01 19:10

  Jyong Biotech files Form 3 initial beneficial ownership statement for director Fan Hung-Shu

• Reuters·04/01 18:57

  Jyong Biotech director Chi Pang-Chieh files initial beneficial ownership statement